Has Yon Chong received payments from drug or device companies?

Yes. Drug and device makers reported $59,083 in general payments to Yon Chong across 368 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Yon Chong did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Yon Chong come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Yon Chong

Psychiatry · Omaha, NENPI 1487909453

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $49,688 of the $59,083 with a category attached, or 84.1%. Supernus Pharmaceuticals, Inc. accounts for 91.4% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $53,079, more than ten times the $1,576 reported in 2019. Among psychiatry clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$59,083in general payments, 2019–2025

Across 368 payments — averaging $160.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Supernus Pharmaceuticals, Inc.$54K
Sunovion Pharmaceuticals Inc.$2K
Alkermes, Inc.$864
Johnson & Johnson$630
Otsuka America Pharmaceutical, Inc.$576
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$348
plus $865 from 10 others

What the payments were for

Speaking & faculty fees$49,68884%
Travel & lodging$1,8623%
Food & beverage$7,48613%
Education$470%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Supernus Pharmaceuticals, Inc.	101	$54,031
Sunovion Pharmaceuticals Inc.	87	$1,769
Alkermes, Inc.	37	$864
Johnson & Johnson	32	$630
Otsuka America Pharmaceutical, Inc.	35	$576
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	23	$348
Takeda Pharmaceuticals U.S.A., Inc.	11	$213
Shire North American Group Inc	12	$153
Neurocrine Biosciences, Inc.	5	$141
Vanda Pharmaceuticals Inc.	10	$116
Vertical Pharmaceuticals, LLC	6	$95
Ironshore Pharmaceuticals Inc.	3	$45
Tris Pharma Inc	2	$37
Lundbeck LLC	2	$27
Jazz Pharmaceuticals Inc.	1	$19
Neuronetics, Inc.	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$59,083 in reported general payments places this provider in the 95th percentile of 160 psychiatry providers in Nebraska.

See all psychiatry providers in Nebraska →

Other psychiatry in Omaha

Vithyalakshmi SelvarajOmaha$1.2M
Sarit HovavOmaha$307K
Mary Jo HaniganOmaha$119K
Syed SattarOmaha$16K
Michael SedlacekOmaha$15K
Sriram RamaswamyOmaha$13K
Elizabeth FitzpatrickOmaha$10K
Praveen FernandesOmaha$5K
Natalie BakerOmaha$4K
Michael EggerOmaha$3K

See the full list for Nebraska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →